Human Vaccines Market Research Report - Middle East and Africa Forecast to 2032

Human Vaccines Market Research Report Information By Technology (Attenuated, Inactivated, Toxoid, Conjugate & Subunit, and Recombinant DNA), By Route of Administration (Oral, Injectable, and Other), By Type (Prophylactic, and Therapeutic), By Disease Indication (Pneumococcal, Influenza, Hepatitis, Rotavirus, DTP, Polio, and Others), By End User (Children, and Adults), By Composition (Mono Vaccine, and Combination Vaccine) And By Countries (Middle East and Africa) –Market Forecast Till 2032

ID: MRFR/Pharma/1984-HCR | 84 Pages | Author: Rahul Gotadki | September 2023         

Table of Content

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure:

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s Five Forces Model

4.1.1 Bargaining Power of suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Middle East and Africa Human Vaccines Market, by Technology

5.1 Introduction

5.1.1 Attenuated

5.1.2 Inactivated

5.1.3 Toxoid

5.1.4 Conjugate and Subunit

5.1.5 Recombinant DNA

6 Middle East and Africa Human Vaccines Market, by Disease Indication

6.1 Introduction

6.1.1 Pneumococcal

6.1.2 Influenza

6.1.3 Hepatitis

6.1.4 Rotavirus

6.1.5 DTP

6.1.6 Polio

6.1.7 Others

7 Middle East and Africa Human Vaccines Market, by Type

7.1 Introduction

7.1.1 Prophylactic

7.1.2 Therapeutic

8 Middle East and Africa Human Vaccines Market, by Composition

8.1 Introduction

8.1.1 Mono vaccine and

8.1.2 Combination vaccines

9 Middle East and Africa Human Vaccines Market, by Route of Administration

9.1 Introduction

9.1.1 Oral

9.1.2 Injectible

9.1.3 Others

10 Middle East and Africa Human Vaccines Market, by End User

10.1 Introduction

10.1.1 Children

10.1.2 Adults

11 Middle East and Africa Human Vaccines Market, by Country

11.1 Introduction

11.1.2 UAE

11. 1.3 Egypt

11. 1.4 Saudi Arabia

11. 1.5 Kuwait

11. 1.6 Qatar

11. 1.7 Oman

12 Company Landscape

12.1 Introduction

12.1.1 Mergers Acquisitions

12.1.2 Collaborations

12.1.3 Release/New Product Launches

12.1.4 Other (Expansion, Updates, Partnership)

13 Company Profile

13.1 GlaxoSmithKline Plc.

13.1.1 Company Overview

13.1.2 Product/Business Segment Overview

13.1.3 Financials

13.1.4 Key Developments

13.1.5 SWOT Analysis

13.2 Merck & Co. Inc.

13.2.1 Overview

13.2.2 Product/Business Segment Overview

13.2.3 Financials

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Pfizer, Inc.

13.3.1 Overview

13.3.2 Product/Business Segment Overview

13.3.3 Financials

13.3.4 Key Developments

13.3.5 SWOT Analysis

13.4 Sanofi Pasteur, Inc.

13.4.1 Overview

13.4.2 Product/Business Segment Overview

13.4.3 Financials

13.4.4 Key Developments

13.4.5 SWOT Analysis

13.5 AstraZeneca Plc.

13.5.1 Overview

13.5.2 Product/Business Segment Overview

13.5.3 Financials

13.5.4 Key Developments

13.5.5 SWOT Analysis

13.6 Bharat Biotech

13.6.1 Overview

13.6.2 Product/Business Segment Overview

13.6.3 Financials

13.6.4 Key Developments

13.6.5 SWOT Analysis

13.7 Shenzhen Kangtai Biological Products

13.7.1 Overview

13.7.2 Product/Business Segment Overview

13.7.3 Financials

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 Valeant Pharmaceuticals

13.8.1 Overview

13.8.2 Product/Business Segment Overview

13.8.3 Financials

13.8.4 Key Developments

13.8.5 SWOT Analysis

13.9 Emergent Biosolutions Inc.

13.9.1 Overview

13.9.2 Product/Business Segment Overview

13.9.3 Financials

13.9.4 Key Developments

13.9.5 SWOT Analysis

13.10 Astellas Pharma Inc.

13.10.1 Overview

13.10.2 Product/Business Segment Overview

13.10.3 Financials

13.10.4 Key Developments

13.10.5 SWOT Analysis

13.11 Panacea Biotec

13.11.1 Overview

13.11.2 Product/Business Segment Overview

13.11.3 Financials

13.11.4 Key Developments

13.11.5 SWOT Analysis

14 Others

15 Appendix

List of Tables

TABLE 1 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, 2023-2030 (USD MILLION)

TABLE 2 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY COMPOSITION, 2023-2030 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY END USER, 2023-2030 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY REGION, 2023-2030 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TECHNOLOGY

FIGURE 4 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY DISEASE INDICATION

FIGURE 5 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TYPE

FIGURE 6 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY COMPOSITION

FIGURE 7 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION

FIGURE 8 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY END USER

FIGURE 9 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY REGION

FIGURE 10 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

Human Vaccines Market Segmentation


Vaccines Technology Outlook (USD Billion, 2018-2032)




  • Attenuated




  • Inactivated




  • Toxoid




  • Conjugate & Subunit




  • Recombinant DNA




Middle East and Africa Human Vaccines Route of Administration Outlook (USD Billion, 2018-2032)




  • Oral




  • Injectable




  • Other




Middle East and Africa Human Vaccines Type Outlook (USD Billion, 2018-2032)




  • Prophylactic




  • Therapeutic




Middle East and Africa Human Vaccines Disease Indication Outlook (USD Billion, 2018-2032)




  • Pneumococcal




  • Influenza




  • Hepatitis




  • Rotavirus




  • DTP




  • Polio




  • Others




Middle East and Africa Human Vaccines End User Outlook (USD Billion, 2018-2032)




  • Children




  • Adults




Middle East and Africa Human Vaccines Composition Outlook (USD Billion, 2018-2032)




  • Mono Vaccine




  • Combination Vaccine




Middle East and Africa Human Vaccines Regional Outlook (USD Billion, 2018-2032)





    • GCC Countries Outlook (USD Billion, 2018-2032)




    • GCC Countries Human Vaccines by Technology




      • Attenuated




      • Inactivated




      • Toxoid




      • Conjugate & Subunit




      • Recombinant DNA






    • GCC Countries Human Vaccines by Route of Administration




      • Oral




      • Injectable




      • Other






    • GCC Countries Human Vaccines by Type




      • Prophylactic




      • Therapeutic






    • GCC Countries Human Vaccines by Disease Indication




      • Pneumococcal




      • Influenza




      • Hepatitis




      • Rotavirus




      • DTP




      • Polio




      • Others






    • GCC Countries Human Vaccines by End User




      • Children




      • Adults






    • GCC Countries Human Vaccines by Composition




      • Mono Vaccine




      • Combination Vaccine






    • South Africa Outlook (USD Billion, 2018-2032)




    • South Africa Human Vaccines by Technology




      • Attenuated




      • Inactivated




      • Toxoid




      • Conjugate & Subunit




      • Recombinant DNA






    • South Africa Human Vaccines by Route of Administration




      • Oral




      • Injectable




      • Other






    • South Africa Human Vaccines by Type




      • Prophylactic




      • Therapeutic






    • South Africa Human Vaccines by Disease Indication




      • Pneumococcal




      • Influenza




      • Hepatitis




      • Rotavirus




      • DTP




      • Polio




      • Others






    • South Africa Human Vaccines by End User




      • Children




      • Adults






    • South Africa Human Vaccines by Composition




      • Mono Vaccine




      • Combination Vaccine






    • Rest of MEA Outlook (USD Billion, 2018-2032)




    • Rest of MEA Human Vaccines by Technology




      • Attenuated




      • Inactivated




      • Toxoid




      • Conjugate & Subunit




      • Recombinant DNA






    • Rest of MEA Human Vaccines by Route of Administration




      • Oral




      • Injectable




      • Other






    • Rest of MEA Human Vaccines by Type




      • Prophylactic




      • Therapeutic






    • Rest of MEA Human Vaccines by Disease Indication




      • Pneumococcal




      • Influenza




      • Hepatitis




      • Rotavirus




      • DTP




      • Polio




      • Others






    • Rest of MEA Human Vaccines by End User




      • Children




      • Adults






    • Rest of MEA Human Vaccines by Composition




      • Mono Vaccine




      • Combination Vaccine






Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid